EE87 Economic Evauation of Adalimumab Biosimilars and JAK Inhibitors for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Abstract

Authors

I Rickard E Carmona T Lessing M Furrer S Keady

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×